Dry Age Related Macular Degeneration (AMD) Market Report 2026

Dry Age Related Macular Degeneration (AMD) Market Overview

• Dry Age Related Macular Degeneration (AMD) market size has reached to $4.89 billion in 2025 • Expected to grow to $7.36 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Rising Geriatric Population To Drive The Market Growth • Market Trend: Advancements In Dry AMD Treatment Lumithera's Valeda Light Delivery System • North America was the largest region in 2025.

What Is Covered Under Dry Age Related Macular Degeneration (AMD) Market?

Dry age related macular degeneration (AMD) refers to a progressive eye condition characterized by the gradual deterioration of the macula, the central part of the retina, leading to blurred central vision. They are used for managing and slowing the progression of the disease through treatments like vitamins, nutritional supplements, and emerging pharmaceutical therapies. The main stages are the dry age related macular degeneration (AMD) of early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration. Early age-related macular degeneration (AMD) is the initial stage of a common eye condition that primarily affects older adults, causing changes in the retina, specifically the macula, which is responsible for central vision. It will attack in different age groups, such as above 75 years, above 60 years, and above 40 years. They treated various routes of administration, oral and injectables, and this is using various end users, like hospitals and clinics, diagnostic centers, and academic and research institutes.

What Is The Dry Age Related Macular Degeneration (AMD) Market Growth Forecast?

The dry age related macular degeneration (amd) market size is expected to see strong growth in the next few years. It will grow to $7.36 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to novel therapeutic pipeline development, precision ophthalmology, ai-based retinal diagnostics, preventive eye care programs, clinical trial investments. Major trends in the forecast period include growing focus on early disease detection, increased use of nutritional supplement therapies, expansion of research on disease-modifying drugs, rising adoption of advanced retinal imaging, increasing patient awareness and screening.

Global Dry Age Related Macular Degeneration (AMD) Market Segmentation

1) By Stages: Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration 2) By Age Group: Above 75 Years, Above 60 Years, Above 40 Years 3) By Route Of Administration: Oral, Injectables 4) By End Users: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes Subsegments: 1) By Early Age-Related Macular Degeneration: Drusen Accumulation, Retinal Pigment Epithelium Changes 2) By Intermediate Age-Related Macular Degeneration: Larger Drusen Deposits, Increased Pigmentary Abnormalities 3) By Late Age-Related Macular Degeneration: Geographic Atrophy, Central Vision Loss

What Is The Driver Of The Dry Age Related Macular Degeneration (AMD) Market?

The growing geriatric population is expected to propel the growth of the dry age-related macular degeneration (AMD) market going forward. The geriatric population refers to individuals aged 65 years and older who experience age-related physiological changes that increase their need for healthcare and vision-care services. The geriatric population is rising due to increased life expectancy, improved chronic-disease management, advancements in medical technology, and expanded access to geriatric care worldwide. The dry age-related macular degeneration (AMD) supports this trend by offering targeted therapies and management solutions that help slow retinal degeneration and preserve vision among older adults. For instance, in July 2023, according to the United Nations, a US-based intergovernmental organization, the global population aged 65 years and older reached 0.77 billion in 2022 and is projected to approach 1.0 billion by 2030. Therefore, the growing geriatric population is driving the growth of the dry age-related macular degeneration (AMD) market.

Key Players In The Global Dry Age Related Macular Degeneration (AMD) Market

Major companies operating in the dry age related macular degeneration (amd) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Apellis Pharmaceuticals Inc., Belite Bio Inc., Alkeus Pharmaceuticals Inc., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc., Regeneron Pharmaceuticals Inc., Annexon Biosciences Inc., Stealth BioTherapeutics Corp., Kodiak Sciences Inc., Ionis Pharmaceuticals Inc., Lineage Cell Therapeutics Inc., Ocular Therapeutix Inc.

Global Dry Age Related Macular Degeneration (AMD) Market Trends and Insights

Major companies operating in the dry age-related macular degeneration (AMD) market are focusing on developing advanced technologies such as light delivery systems to activate retinal cells, improve visual function, and potentially slow disease progression. Light delivery systems refer to therapeutic devices designed to deliver controlled wavelengths of light to targeted retinal tissues, stimulating cellular activity and supporting retinal health through non-invasive photobiomodulation techniques. For instance, in January 2024, LumiThera Inc., a US-based medical device company, launched photobiomodulation therapy for dry AMD using the Valeda Light Delivery System, the first FDA-authorized treatment for vision loss associated with dry AMD. The system utilizes a multi-wavelength light delivery approach employing 590 nm, 660 nm, and 850 nm wavelengths to stimulate retinal cells, and LumiThera has initiated the EUROLIGHT registry study to collect long-term outcome data, with treatments typically administered in nine sessions over a three- to four-week period.

What Are Latest Mergers And Acquisitions In The Dry Age Related Macular Degeneration (AMD) Market?

In May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc. for $5.9 billion. Through this acquisition, Astellas Pharma aims to expand its presence in the ophthalmology market by accelerating the development of novel treatments for retinal diseases and improving outcomes for patients worldwide. IVERIC Bio Inc. is a US-based biotechnology company that develops drugs and therapies for age-related macular degeneration and other retinal conditions.

Regional Outlook

North America was the largest region in the dry age-related macular degeneration (AMD) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Dry Age Related Macular Degeneration (AMD) Market?

The dry age related macular degeneration (AMD) market consists of sales of syfovre, zimura, visudyne, and alk-001. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Dry Age Related Macular Degeneration (AMD) Market Report 2026?

The dry age related macular degeneration (amd) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the dry age related macular degeneration (amd) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.